Rights and permissions
About this article
Cite this article
Prolonged valganciclovir best for CMV in high-risk patients. Pharmacoecon. Outcomes News 638, 9 (2011). https://doi.org/10.2165/00151234-201106380-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106380-00025